Novartis Pharma - Bathi resik saben saham (EPS TTM) NVS

Novartis AG (NVS) maintains a stable moat through its bet on gene therapy and patent-protected innovative developments. The rolling year earnings per share (EPS) reflects this trend, where the 5.26 level captures the current state. While production robotization and AI laboratories optimize costs, geopolitical tensions and sanction risks regarding raw materials complicate logistics and the protection of rights in conflict zones.

NVS (Novartis AG) riwayat Bathi resik saben saham sajrone patang kuartal pungkasan saka 04.07.2022 nganti 15.11.2026

Rincian analitis perusahaan Novartis AG

- kuotasi saiki lan rata-rata prakiraan nilai:

Bagan rega Novartis|NVS - Bagan rega target

- rincian nilai pasar emiten:

Kapitalisasi pasar Novartis|NVS - Nilai Bisnis

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Novartis|NVS - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku novartis.com|NVS - Total Aset Bisnis

- indikator beban utang lan likuiditas:

- indikator pendapatan resik lan kelipatan nilai:

NVS - Bathi resik|Bathi sing dikarepake Novartis AG|NVS - Nilai perusahaan marang bathi resik|Prakiraan rega marang bathi Novartis|NVS - Rasio nilai perusahaan marang wutah bathi|Pangali EV/EBITDA Novartis|NVS - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Novartis|NVS - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan novartis.com|NVS - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Novartis AG

- data total pendapatan lan volume dodolan:

NVS - Pendapatan lan volume dodolan|Prakiraan volume dodolan novartis.com|NVS - Multiplikator rega marang pendapatan|Rasio rega marang prakiraan pendapatan Novartis

Pambiji fundamental:NVS - Novartis Pharma

This metric measures the real return per share by dividing total annual net income by the number of securities to assess the fundamental efficiency of the business. The net income per share trend over the last four quarters reflects the monetization of Novartis AG (NVS) unique biotechnological platforms, confirming the company's financial stability as an indispensable link in the production of innovative gene therapy.

Pesaing utama